These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 25195579)

  • 1. Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
    Cacabelos R
    Drug Dev Res; 2014 Sep; 75(6):348-65. PubMed ID: 25195579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic drug discovery for Alzheimer's disease.
    Cacabelos R; Torrellas C
    Expert Opin Drug Discov; 2014 Sep; 9(9):1059-86. PubMed ID: 24989365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
    Santini V; Gozzini A; Ferrari G
    Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics.
    Duan YT; Sangani CB; Liu W; Soni KV; Yao Y
    Curr Top Med Chem; 2019; 19(12):972-994. PubMed ID: 31161992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
    Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
    Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel cancer drugs based on epigenetics, miRNAs and their interactions.
    Roukos DH
    Epigenomics; 2011 Dec; 3(6):675-8. PubMed ID: 22126285
    [No Abstract]   [Full Text] [Related]  

  • 8. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
    Schneider-Stock R; Ocker M
    IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel approaches on epigenetics.
    Papait R; Monti E; Bonapace IM
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitor and demethylating agent chromatin compaction and the radiation response by cancer cells.
    Bar-Sela G; Jacobs KM; Gius D
    Cancer J; 2007; 13(1):65-9. PubMed ID: 17464248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetics in prostate cancer: biologic and clinical relevance.
    Jerónimo C; Bastian PJ; Bjartell A; Carbone GM; Catto JW; Clark SJ; Henrique R; Nelson WG; Shariat SF
    Eur Urol; 2011 Oct; 60(4):753-66. PubMed ID: 21719191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic small molecule modulators of histone and DNA methylation.
    Hauser AT; Robaa D; Jung M
    Curr Opin Chem Biol; 2018 Aug; 45():73-85. PubMed ID: 29579619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Regulatory Mechanisms Induced by Resveratrol.
    Fernandes GFS; Silva GDB; Pavan AR; Chiba DE; Chin CM; Dos Santos JL
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29104258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
    Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetics and cancer treatment.
    Kristensen LS; Nielsen HM; Hansen LL
    Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Chromatin Remodeling for Cancer Therapy.
    Kaur J; Daoud A; Eblen ST
    Curr Mol Pharmacol; 2019; 12(3):215-229. PubMed ID: 30767757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract.
    Wang Z; Yue Y; Han P; Sa R; Ren X; Wang J; Bai H; Yu H
    Cytotherapy; 2013 Sep; 15(9):1164-73. PubMed ID: 23800731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule inhibitors of histone acetyltransferases as epigenetic tools and drug candidates.
    Furdas SD; Kannan S; Sippl W; Jung M
    Arch Pharm (Weinheim); 2012 Jan; 345(1):7-21. PubMed ID: 22234972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
    Morera L; Lübbert M; Jung M
    Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer type-specific epigenetic changes: gastric cancer.
    Calcagno DQ; de Arruda Cardoso Smith M; Burbano RR
    Methods Mol Biol; 2015; 1238():79-101. PubMed ID: 25421656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.